PMID- 35780639
OWN - NLM
STAT- MEDLINE
DCOM- 20221018
LR  - 20221018
IS  - 1532-8198 (Electronic)
IS  - 1092-9134 (Linking)
VI  - 60
DP  - 2022 Oct
TI  - Comparison of PD-L1 detection methods, platforms and reagents in bladder cancer.
PG  - 151986
LID - S1092-9134(22)00088-0 [pii]
LID - 10.1016/j.anndiagpath.2022.151986 [doi]
AB  - In this retrospective study, we collected 282 bladder cancer patients diagnosed 
      from 2011 to 2018. Two mechanisms, fluorescence in situ hybridization (FISH) and 
      immunohistochemistry (IHC), were used to detect programmed death molecule ligand 
      1 (PD-L1) expression, and these analyses were performed on different platforms 
      using different antibodies (22C3, 28-8, and SP263). The results were compared, 
      and related clinical parameters were analysed to explore the consistencies and 
      correlations between different detection methods, clonal antibodies and platforms 
      for the detection of PD-L1 in bladder cancer patients to more effectively 
      identify patients who are suitable for immunotherapy. The rate of PD-L1 
      positivity with 28-8 (42.3 %) was higher than that with 22C3 (22.1 %) or SP263 
      (22.1 %). The rate of PD-L1 positivity with SP263 was consistent with that of 
      22C3, and patients with positive PD-L1 expression detected by SP263 had longer 
      overall survival in clinical parameter analysis. However, the rate of PD-L1 
      positivity with FISH was only 2.10 %, and the rate of agreement between FISH and 
      IHC was only 1.06 %. In conclusion, the detection of PD-L1 with SP263 and IHC was 
      more consistent and had a higher prognostic value, providing guidance for 
      clinical diagnosis and treatment. The clinical application of FISH for PD-L1 
      detection needs to be further explored.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Weng, Menghan
AU  - Weng M
AD  - Department of Pathology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou 310003, China.
FAU - Bai, Yanfeng
AU  - Bai Y
AD  - Department of Pathology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou 310003, China.
FAU - Xu, Liming
AU  - Xu L
AD  - Department of Pathology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou 310003, China.
FAU - Chang, Chengdong
AU  - Chang C
AD  - Department of Pathology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou 310003, China.
FAU - Teng, Xiaodong
AU  - Teng X
AD  - Department of Pathology, First Affiliated Hospital, Zhejiang University School of 
      Medicine, Hangzhou 310003, China. Electronic address: teng1102069@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220607
PL  - United States
TA  - Ann Diagn Pathol
JT  - Annals of diagnostic pathology
JID - 9800503
RN  - 0 (Antibodies)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Indicators and Reagents)
RN  - 0 (Ligands)
SB  - IM
MH  - Antibodies
MH  - B7-H1 Antigen/metabolism
MH  - Biomarkers, Tumor/analysis
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Indicators and Reagents
MH  - Ligands
MH  - *Lung Neoplasms/metabolism
MH  - Retrospective Studies
MH  - *Urinary Bladder Neoplasms/diagnosis
OTO - NOTNLM
OT  - Bladder cancer
OT  - Clinical Application
OT  - FISH
OT  - IHC
OT  - PD-L1
COIS- Declaration of competing interest None.
EDAT- 2022/07/04 06:00
MHDA- 2022/10/19 06:00
CRDT- 2022/07/03 18:21
PHST- 2022/03/06 00:00 [received]
PHST- 2022/05/02 00:00 [revised]
PHST- 2022/06/03 00:00 [accepted]
PHST- 2022/07/04 06:00 [pubmed]
PHST- 2022/10/19 06:00 [medline]
PHST- 2022/07/03 18:21 [entrez]
AID - S1092-9134(22)00088-0 [pii]
AID - 10.1016/j.anndiagpath.2022.151986 [doi]
PST - ppublish
SO  - Ann Diagn Pathol. 2022 Oct;60:151986. doi: 10.1016/j.anndiagpath.2022.151986. 
      Epub 2022 Jun 7.